3-hydroxy-3-methylglutaryl-coenzyme a has been researched along with Coronary Heart Disease in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Igel, M; Sudhop, T; von Bergmann, K | 1 |
| Tobert, JA | 1 |
| Parhofer, KG; Richter, WO; Schwandt, P | 1 |
| Ballantyne, CM; el Masri, B; Morrisett, JD; Torre-Amione, G | 1 |
| Kellett, J | 1 |
| Jacobson, TA | 1 |
| Beatt, KJ; Khan, M; Malik, IS | 1 |
4 review(s) available for 3-hydroxy-3-methylglutaryl-coenzyme a and Coronary Heart Disease
| Article | Year |
|---|---|
Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin.
Topics: Acyl Coenzyme A; Coronary Disease; Enzyme Inhibitors; Fluorobenzenes; Hypolipidemic Agents; Pyrimidines; Quinolines; Rosuvastatin Calcium; Sulfonamides | 2002 |
Drug therapy of severe hypercholesterolemia in patients with coronary artery disease.
Topics: Acyl Coenzyme A; Anticholesteremic Agents; Bile Acids and Salts; Cholesterol, LDL; Coronary Disease; Drug Synergism; Drug Therapy, Combination; Endothelium, Vascular; Humans; Hypercholesterolemia; Hypolipidemic Agents; Triglycerides | 1996 |
Pathophysiology and treatment of lipid perturbation after cardiac transplantation.
Topics: Acyl Coenzyme A; Animals; Blood Component Removal; Coronary Disease; Cyclosporine; Drug Therapy, Combination; Graft Rejection; Heart Transplantation; Humans; Hyperlipidemias; Immunosuppressive Agents; Lipoproteins; Tacrolimus | 1997 |
"The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline?.
Topics: Acyl Coenzyme A; Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Practice Guidelines as Topic; Risk Factors; Simvastatin | 2000 |
4 other study(ies) available for 3-hydroxy-3-methylglutaryl-coenzyme a and Coronary Heart Disease
| Article | Year |
|---|---|
[Significance of HDL cholesterol increase for the risk reduction. Methods of intervention. recommendations of experts].
Topics: Acyl Coenzyme A; Adult; Anticholesteremic Agents; Cholesterol, HDL; Clofibric Acid; Coronary Disease; Europe; Female; Humans; Male; Niacin; Practice Guidelines as Topic; Risk Factors; Risk Reduction Behavior; Societies, Medical | 2005 |
Blood cholesterol measurement in young adults.
Topics: Acyl Coenzyme A; Cholesterol; Coronary Disease; Humans; Hypolipidemic Agents | 1993 |
Likely gains in life expectancy of patients with coronary artery disease treated with HMG-CoA reductase inhibitors, as predicted by a decision analysis model.
Topics: Acyl Coenzyme A; Adult; Age Distribution; Aged; Aged, 80 and over; Combined Modality Therapy; Coronary Artery Bypass; Coronary Disease; Decision Support Techniques; Female; Humans; Life Expectancy; Male; Middle Aged; Predictive Value of Tests; Prognosis; Survival Rate | 1997 |
Effect of statin therapy on restenosis after coronary stent implantation.
Topics: Acyl Coenzyme A; Cholesterol, LDL; Coronary Disease; Humans; Muscle, Smooth, Vascular; Recurrence; Stents | 2000 |